Trial Report A 6-month Ibudilast treatment regimen aimed to improve brain function in ME/CFS patients: A case study, 2023, Ziaja et al

Mij

Mij

Senior Member (Voting Rights)
A 6-month Ibudilast treatment regimen aimed to improve brain function in ME/CFS patients: A case study

https://www.jns-journal.com/article/S0022-510X(23)01613-1/fulltext

Background: ME/CFS is a complex multisystemic post-viral syndrome with heterogeneous symptoms, possibly related to virus or immune-mediated disruption. MR scans using Fractional Anisotropy could identify differences in fibre connectivity of ME/CFS patients compared to healthy controls. This might be a result of an inflammatory process in the brain of ME/CFS patients. This might contribute to one of patients` major complaint: brain fog.
 
Last edited by a moderator:
December 22, 2023

MediciNova files patent for method of treating post-covid condition using ibuilast
A recently filed patent (Publication Number: US20230285367A1) describes a method for treating post-COVID conditions in patients. The method involves administering ibudilast, or a pharmaceutical salt thereof, in a therapeutically effective amount to the patient.

The post-COVID conditions that can be treated using this method include anxiety, general pain or discomfort, fatigue, insomnia, cognitive impairment, depression, shortness of breath, post-traumatic stress disorder, joint pain, muscle pain, chest pain or tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash. Specifically, cognitive impairment can include memory lapse and impaired concentration.

The administration of ibudilast can be done through various routes, including oral, intravenous, subcutaneous or intramuscular injection, and inhalation. The duration of administration can range from 1 to 10 days or more, with a minimum of 2 months for effective treatment. Ibudilast can be administered once or twice daily, and the therapeutically effective amount can vary from 0.1 mg to 720 mg per day. The recommended range for effective treatment is 30 mg to 200 mg per day, or 60 mg to 600 mg daily. The therapeutically effective amount can be given as a single dose or divided into multiple doses.

In some cases, ibudilast can be the only active agent administered to the patient, while in others, it can be combined with other active agents. The additional active agents can include corticosteroids, COX-2 inhibitors, NSAIDs, SSRIs, SNRIs, tricyclic antidepressants, antihistamines, beta-blockers, cannabidiol, ATP, ifenprodil tartrate, neurotropin, gabapentin, pregabalin, mirtazapine, or a combination of two or more of these agents.

This patent filing provides a method for treating various post-COVID conditions using ibudilast, either alone or in combination with other active agents. The flexibility in administration routes, dosage, and duration allows for personalized treatment based on the specific condition and needs of the patient. Further research and clinical trials will be necessary to validate the effectiveness and safety of this method.
Click to expand...
https://www.pharmaceutical-technolo...um=24-257105&utm_campaign=recommended-article
 
You must log in or register to reply here.
Back
Top Bottom